Joel Beatty

Stock Analyst at Baird

(4.63)
# 209
Out of 5,147 analysts
209
Total ratings
53.33%
Success rate
35.33%
Average return

Stocks Rated by Joel Beatty

Praxis Precision Medicines
Feb 20, 2026
Maintains: Outperform
Price Target: $275$433
Current: $336.75
Upside: +28.58%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72$47
Current: $23.39
Upside: +100.94%
Contineum Therapeutics
Nov 24, 2025
Maintains: Outperform
Price Target: $16$14
Current: $15.34
Upside: -8.74%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160$209
Current: $190.02
Upside: +9.99%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145$125
Current: $92.05
Upside: +35.80%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10$19
Current: $15.17
Upside: +25.25%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10$7
Current: $5.31
Upside: +31.83%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50$67
Current: $55.19
Upside: +21.40%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4$6
Current: $2.20
Upside: +172.73%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7$9
Current: $38.85
Upside: -76.83%
Maintains: Outperform
Price Target: $28$31
Current: $24.56
Upside: +26.22%
Downgrades: Neutral
Price Target: $38$24
Current: $23.49
Upside: +2.17%
Upgrades: Outperform
Price Target: $680
Current: $766.92
Upside: -11.33%
Maintains: Outperform
Price Target: $30$29
Current: $21.18
Upside: +36.92%
Maintains: Outperform
Price Target: $70$66
Current: $68.19
Upside: -3.21%
Maintains: Outperform
Price Target: $160$162
Current: $163.89
Upside: -1.15%
Maintains: Outperform
Price Target: $38$41
Current: $30.10
Upside: +36.21%
Maintains: Outperform
Price Target: $28$32
Current: $23.08
Upside: +38.65%
Initiates: Outperform
Price Target: $75
Current: $83.82
Upside: -10.52%
Maintains: Outperform
Price Target: $6$7
Current: $2.80
Upside: +150.00%
Maintains: Neutral
Price Target: $72$65
Current: $61.73
Upside: +5.30%
Maintains: Outperform
Price Target: $540$240
Current: $0.79
Upside: +30,101.98%
Downgrades: Neutral
Price Target: $4.5
Current: $1.68
Upside: +167.86%
Maintains: Outperform
Price Target: $24$25
Current: $15.97
Upside: +56.54%
Maintains: Outperform
Price Target: $32$28
Current: $21.71
Upside: +28.97%
Initiates: Outperform
Price Target: $16
Current: $1.29
Upside: +1,140.31%
Maintains: Outperform
Price Target: $4$1.25
Current: $1.35
Upside: -7.41%
Initiates: Outperform
Price Target: $44
Current: $1.30
Upside: +3,284.62%
Maintains: Outperform
Price Target: $60$58
Current: $63.27
Upside: -8.33%
Maintains: Outperform
Price Target: $18$24
Current: $32.20
Upside: -25.47%
Downgrades: Underperform
Price Target: $18
Current: $8.23
Upside: +118.71%
Maintains: Outperform
Price Target: $9$6
Current: $1.94
Upside: +209.28%
Upgrades: Neutral
Price Target: $36$28
Current: $9.09
Upside: +208.03%
Downgrades: Neutral
Price Target: $170$175
Current: $332.92
Upside: -47.43%
Downgrades: Neutral
Price Target: $14
Current: $8.91
Upside: +57.13%
Downgrades: Neutral
Price Target: $108
Current: $16.76
Upside: +544.39%
Maintains: Buy
Price Target: $80$78
Current: $81.15
Upside: -3.88%
Maintains: Buy
Price Target: $140$100
Current: $20.99
Upside: +376.42%
Maintains: Buy
Price Target: $480$120
Current: $13.80
Upside: +769.57%
Maintains: Buy
Price Target: $480$450
Current: $3.44
Upside: +12,981.40%
Upgrades: Buy
Price Target: n/a
Current: $3.35
Upside: -
Maintains: Buy
Price Target: $19$15
Current: $10.14
Upside: +47.93%
Upgrades: Neutral
Price Target: $14$11
Current: $12.35
Upside: -14.98%
Maintains: Neutral
Price Target: $2,400$1,200
Current: $0.19
Upside: +648,548.65%
Maintains: Buy
Price Target: $15$19
Current: $8.73
Upside: +117.64%